Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial
Authors:
- 18 November 2024
- journal article
- research article
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 10 (1) , 26-33
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Real-World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2023
- Parametric and nonparametric methods for confidence intervals and sample size planning for win probability in parallel‐group randomized trials with Likert item and Likert scale dataPharmaceutical Statistics, 2022
- Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn’s Disease: A Meta-Analysis of Population-Based CohortsClinical Gastroenterology and Hepatology, 2021
- Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2020
- Crohn's disease management after intestinal resection: a randomised trialThe Lancet, 2015
- Crohnʼs disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resectionInflammatory Bowel Diseases, 2011
- Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohnʼs disease after ileo-caecal resectionInflammatory Bowel Diseases, 2007
- Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileumGastroenterology, 1998
- Controlled trial of metronidazole treatment for prevention of crohn's recurrence after ileal resectionGastroenterology, 1995
- Predictability of the postoperative course of Crohn's diseaseGastroenterology, 1990